Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan

por Sugamori, Haruko, Lee, Takumi, Mitomi, Takeshi, Yamagishi, Chika
Publicado 2022

A multicenter, retrospective observational study investigating baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer treated with primar...

por Taguchi, Satoru, Onozawa, Mizuki, Hinotsu, Shiro, Kawai, Taketo, Mitomi, Takeshi, Uno, Satoshi, Kume, Haruki
Publicado 2023